Centre Georges-François Leclerc
- Address
- 1 rue du Pr Marion, 21000 Dijon, France
Pediatric Neuroblastoma Research
The department investigates high‑risk neuroblastoma, an aggressive childhood cancer, aiming to improve three‑year event‑free survival by comparing intensive chemotherapy approaches and adding immunotherapy for patients with limited response.
- Comparison of single high‑dose chemotherapy versus tandem regimens
- Evaluation of post‑induction chemoimmunotherapy to boost metastatic response
- Optimization of radiotherapy dosing for residual tumor after surgery
At Centre Georges‑François Leclerc, the multidisciplinary team collaborates with European networks to refine treatment strategies for this challenging disease.
Advanced Colorectal Cancer Trials
Research targets unresectable locally advanced or metastatic colorectal cancer in adults, focusing on safety and efficacy of a novel agent combined with standard therapy to establish optimal dosing and therapeutic benefit.
- Safety profiling and dose‑finding of the investigational combination
- Measurement of clinical efficacy when added to standard chemotherapy
- Exploration of biomarkers that predict treatment response
The site in Dijon contributes to early‑phase studies that could expand therapeutic options for patients with advanced digestive system cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Brenus Pharma1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Georges-François Leclerc
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Study of Busulfan, Melphalan, and Chemoimmunotherapy in High-Risk Neuroblastoma Patients with Insufficient Metastatic Response | Institut Gustave Roussy | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anhydrous Cyclophosphamide | 1 | Unknown | 2025-06-17 | 2025-06-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.